A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.
Case: A 74-Year-Old Man with Diffuse Large B-Cell Lymphoma
Initial Presentation
- A 74-year-old man presented with fever, 14-lb unintentional weight loss and occasional chest pain
- PMH: DM, medically controlled
- PE: tired-appearing man; palpable bilateral cervical lymphadenopathy
Clinical Work-up
- Labs: LDH 2 times above normal; Hb 10.8 g/dL; bilirubin 2.3 mg/dL; creatinine 1.7 mg/fl; all others WNL
- Hepatitis B, C and HIV negative
- Lymph node biopsy; CD 20+ confirmed DLBCL; IHC panel: CD 10+, CD 19+
- Imaging:
- Whole body PET/CT scan showed activity the cervical lymph node region, largest node 2.5 cm; evidence of axillary and thoracic subcutaneous tissue involvement
- Ann Arbor stage 4; IPI: high-risk; ECOG PS 1
Treatment
- Treatment initiated with R-CHOP + RT; well-tolerated
- Interim PET scan after 4 cycles; progressive diseases noted
- Due to transplant ineligibility patient was treated with tafasitamab + lenalidomide
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL
August 15th 2024During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
Takeaways on Tolerability Challenges With Loncastuximab in DLBCL
July 30th 2024During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
